Seelos Therapeutics doses first patients in ethnobridging study with SLS-002

Seelos Therapeutics announced that it has dosed the first patients in an ethnobridging study in healthy adult Japanese and non-Asian subjects to compare the safety and pharmacokinetic profiles of SLS-002. Seelos consulted and received endorsement from the Pharmaceuticals and Medical Devices Agency in Japan and from the U.S. FDA to conduct this Phase I ethnobridging study. Study SLS-002-103 will measure elements such as dosage and administration, sample size, inclusion and exclusion criteria, endpoints, and blood sampling. Seelos expects that data from this study will help inform inclusion of Japanese subjects in the design of a future global trial in patients with major depressive disorder at imminent risk of suicide.